CDK4/6 Inhibitors—Overcoming Endocrine Resistance Is the Standard in Patients with Hormone Receptor-Positive Breast Cancer
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Erschienen in
-
In: Cancers 15.6 (2023): 1763.
- Ereignis
-
Veröffentlichung
- (wo)
-
Erlangen
- (wer)
-
Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU)
- (wann)
-
2023
- Urheber
-
Nabieva, Naiba
Fasching, Peter A.
- DOI
-
10.3390/cancers15061763
- URN
-
urn:nbn:de:bvb:29-opus4-225747
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
25.03.2025, 13:53 MEZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Nabieva, Naiba
- Fasching, Peter A.
- Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU)
Entstanden
- 2023
Ähnliche Objekte (12)
Endocrine Treatment for Breast Cancer Patients Revisited—History, Standard of Care, and Possibilities of Improvement
Mammographic texture as new and independent breast cancer risk factor
Teilnahmerate an einer chemopräventiven Behandlung in der IBIS-II-Studie : eine prospektive Kohortenstudie im Rahmen des Mammographiescreenings
Methoden der Statistik zur Analyse von Single Nucleotide Polymorphism (SNP) anhand der Auswertung von Genotypdaten aus einer neoadjuvanten Chemotherapiestudie
Untersuchung der Invasivität von primären Endometriosezellen
Invasive Breast Cancer: Recognition of Molecular Subtypes
Cost-Benefit Analysis of Endocrine Therapy in the Adjuvant Setting for Postmenopausal Patients with Hormone Receptor-Positive Breast Cancer, Based on Survival Data and Future Prices for Generic Drugs in the Context of the German Health Care System
Are Certified Breast Centers Cost-Effective?
Breast Tumor Analysis Using Shifted-Excitation Raman Difference Spectroscopy (SERDS)
The integrative epigenomic-transcriptomic landscape of ER positive breast cancer
Expression of Neuroendocrine Markers in Different Molecular Subtypes of Breast Carcinoma
![Endocrine therapy of breast cancer, [1]](/assets/placeholder/searchResultMediaNoDigitisedMedia.png)
Endocrine therapy of breast cancer, [1]
Endocrine Treatment for Breast Cancer Patients Revisited—History, Standard of Care, and Possibilities of Improvement
Mammographic texture as new and independent breast cancer risk factor
Teilnahmerate an einer chemopräventiven Behandlung in der IBIS-II-Studie : eine prospektive Kohortenstudie im Rahmen des Mammographiescreenings
Methoden der Statistik zur Analyse von Single Nucleotide Polymorphism (SNP) anhand der Auswertung von Genotypdaten aus einer neoadjuvanten Chemotherapiestudie
Untersuchung der Invasivität von primären Endometriosezellen
Invasive Breast Cancer: Recognition of Molecular Subtypes
Cost-Benefit Analysis of Endocrine Therapy in the Adjuvant Setting for Postmenopausal Patients with Hormone Receptor-Positive Breast Cancer, Based on Survival Data and Future Prices for Generic Drugs in the Context of the German Health Care System
Are Certified Breast Centers Cost-Effective?
Breast Tumor Analysis Using Shifted-Excitation Raman Difference Spectroscopy (SERDS)
The integrative epigenomic-transcriptomic landscape of ER positive breast cancer
Expression of Neuroendocrine Markers in Different Molecular Subtypes of Breast Carcinoma
Endocrine therapy of breast cancer, [1]
Endocrine Treatment for Breast Cancer Patients Revisited—History, Standard of Care, and Possibilities of Improvement
Mammographic texture as new and independent breast cancer risk factor
Teilnahmerate an einer chemopräventiven Behandlung in der IBIS-II-Studie : eine prospektive Kohortenstudie im Rahmen des Mammographiescreenings
Methoden der Statistik zur Analyse von Single Nucleotide Polymorphism (SNP) anhand der Auswertung von Genotypdaten aus einer neoadjuvanten Chemotherapiestudie
Untersuchung der Invasivität von primären Endometriosezellen
Invasive Breast Cancer: Recognition of Molecular Subtypes
Cost-Benefit Analysis of Endocrine Therapy in the Adjuvant Setting for Postmenopausal Patients with Hormone Receptor-Positive Breast Cancer, Based on Survival Data and Future Prices for Generic Drugs in the Context of the German Health Care System
Are Certified Breast Centers Cost-Effective?
Breast Tumor Analysis Using Shifted-Excitation Raman Difference Spectroscopy (SERDS)
The integrative epigenomic-transcriptomic landscape of ER positive breast cancer
Expression of Neuroendocrine Markers in Different Molecular Subtypes of Breast Carcinoma